Teva is looking to evolve its business through ... of the drug from the 1990s helped create the problem. Against this background, gaining approval and health insurance coverage for AD drugs ...

Non-GAAP net profit was $57.3 million in the fourth quarter, up 70% from the fourth quarter of 2023 and earnings per share ...

Previously, Medley was the Head of Business Development at Ghost Robot in New York City. Now reporting directly to LOS YORK ...

Ben Hargreaves examines why these shortages are happening and what is being done in the background to return supply ... Hikma Pharmaceutical, and Teva Pharmaceuticals) posted their own reasons ...

let’s take a look at some background. Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in ...

Background Maintenance and reliever therapy (MART ... In this study, we evaluated the efficacy and safety of budesonide/formoterol (160/4.5 µg dry powder via Spiromax, TEVA, corresponding to 200/6 µg ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...

Shares of Teva Pharmaceutical Industries (NYSE: TEVA) were slipping Wednesday. The company's stock lost 13.5% as of 1:15 p.m. ET. The leg down comes as the S&P 500 (SNPINDEX: ^GSPC) and Nasdaq ...

Alvotech (ALVO) and Teva Pharmaceuticals (TEVA) announced that the FDA has accepted for review a Biologics License Application, or BLA, for AVT06, Alvotech’s proposed biosimilar to Eylea ...

2025 Free Cash Flow Guidance: $1.6 billion to $1.9 billion. Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported a 9% increase in revenue for 2024, reaching $16.5 billion, driven by strong ...

The FDA has accepted Alvotech (NASDAQ:ALVO) and Teva's (NYSE:TEVA) Biologics License Applications for AVT05, their proposed biosimilar to the anti-inflammatory drugs Simponi and Simponi Aria.